Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsPaul Wang, MD
Associate Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Biography
Dr. Wang is a developmental-behavioral pediatrician who has worked in academia, large pharma, start-up biotech, and the non-profit sector. Since 2002, his career has focused on drug development, especially for autism and related genetic disorders. He led pioneering trials for Fragile X syndrome, 16p11.2 deletion syndrome, and autism. Currently at the Simons Foundation, he continues to focus on trial design, the development and validation of outcome measures for autism, and biomarker strategy for autism drug development. He is a member of the federally-appointed Interagency Autism Coordinating Committee, and has served in leadership positions for the American Academy of Pediatrics, the American Board of Pediatrics, and other professional groups.
Last Updated on March 28, 2025.
Departments & Organizations
Education & Training
- Clinical fellow
- Children's Hospital of Philadelphia (1995)
- Research fellow (Pediatric Scientist Development Program)
- Salk Institute for Biological Studies (1993)
- Resident/Chief Resident
- University of Michigan Medical center (1990)
- MD
- Yale School of Medicine (1986)
- AB
- Harvard College (1982)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Paul Wang's published research.
Publications Timeline
A big-picture view of Paul Wang's research output by year.
Ellen J. Hoffman, MD, PhD
Kristen Brennand, PhD
Rebecca Muhle, MD, PhD
Stuart Alan Weinzimer, MD
45Publications
4,748Citations
Publications
2025
A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes
Thom R, Warren T, Khan S, Muhle R, Wang P, Brennand K, Zürcher N, Veenstra-VanderWeele J, Hoffman E. A Blueprint for Translational Precision Medicine in Autism Spectrum Disorder and Related Neurogenetic Syndromes. Journal Of Child And Adolescent Psychopharmacology 2025, 35: 178-193. PMID: 40138183, PMCID: PMC12344128, DOI: 10.1089/cap.2025.0023.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAutism spectrum disorderNeurogenetic syndromesSpectrum disorderNeurobiology of autism spectrum disordersRett syndromeTarget engagementEvaluation of target engagementPlacebo responseEvaluate target engagementClinical trialsClinical trial design strategiesIntermediate phenotypesPreclinical model systemsTreatment discoveryObjectives:Trial design strategiesTrofinetideMolecular targetsNeurobiologyFace validityHuman clinical trialsPrecision medicineStem cell model systemsPrecision medicine approachIdentification of molecular targets
2021
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities
Krishnan M, Berry-Kravis E, Capal J, Carpenter R, Gringras P, Hipp J, Miller M, Mingorance A, Philpot B, Pletcher M, Rotenberg A, Tjeertes J, Wang P, Willgoss T, de Wit M, Jeste S. Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities. Nature Reviews Drug Discovery 2021, 20: 653-654. PMID: 34002058, DOI: 10.1038/d41573-021-00085-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsA white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders
Díaz-Caneja C, State M, Hagerman R, Jacquemont S, Marín O, Bagni C, Umbricht D, Simonoff E, de Andrés-Trelles F, Kaale A, Pandina G, Gómez-Mancilla B, Wang P, Cusak J, Siafis S, Leucht S, Parellada M, Loth E, Charman T, Buitelaar J, Murphy D, Arango C. A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. European Neuropsychopharmacology 2021, 48: 49-88. PMID: 33781629, DOI: 10.1016/j.euroneuro.2021.02.020.Peer-Reviewed Original ResearchCitationsAltmetric
2018
Implicit Learning in Children and Adults With Williams Syndrome
Don A, Schellenberg E, Reber A, DiGirolamo K, Wang P. Implicit Learning in Children and Adults With Williams Syndrome. 2018, 201-225. DOI: 10.4324/9780203764800-9.Peer-Reviewed Original ResearchConceptsImplicit learningWilliams syndromeComparison groupEvidence of implicit learningRotor pursuit taskNonverbal intelligenceWorking memoryGroup of childrenWS groupGroup differencesLearning paradigmChronological ageIndependent of ageImplicitTaskAdultsIQLearningDevelopmental processesMemoryChildrenParticipantsParadigmWilliamGroup
2017
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis E, Lindemann L, Jønch A, Apostol G, Bear M, Carpenter R, Crawley J, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf S, Wang P, Von Raison F, Hagerman R, Spooren W, Jacquemont S. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature Reviews Drug Discovery 2017, 17: 280-299. PMID: 29217836, PMCID: PMC6904225, DOI: 10.1038/nrd.2017.221.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFragile X mental retardation protein 1X syndromeNeurodevelopmental disorder associated with intellectual disabilityDisorder associated with intellectual disabilityMetabotropic glutamate receptor 5Fmr1 knockout miceAssessment of cognitionAutism spectrum disorderGlutamate receptor 5Fragile X syndromeNeurobiological mechanismsIntellectual disabilityBehavioral measuresBehavioral phenotypesSpectrum disorderNeurodevelopmental disordersSynaptic plasticityCore phenotypeGABA receptorsDevelopmental outcomesClinical trialsYoung childrenCognitionSecondary behaviorDisordersAdaptive behavior in autism: Minimal clinically important differences on the Vineland‐II
Chatham C, Taylor K, Charman T, D'ardhuy X, Eule E, Fedele A, Hardan A, Loth E, Murtagh L, del Valle Rubido M, San Jose Caceres A, Sevigny J, Sikich L, Snyder L, Tillmann J, Ventola P, Walton‐Bowen K, Wang P, Willgoss T, Bolognani F. Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II. Autism Research 2017, 11: 270-283. PMID: 28941213, PMCID: PMC5997920, DOI: 10.1002/aur.1874.Peer-Reviewed Original ResearchCitationsAltmetricArbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann W, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear M, Carpenter R. Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal Of Neurodevelopmental Disorders 2017, 9: 3. PMID: 28616094, PMCID: PMC5467054, DOI: 10.1186/s11689-016-9181-6.Peer-Reviewed Original ResearchCitationsAltmetricConceptsClinical Global Impression-ImprovementFragile X syndromeClinical Global Impression-SeveritySocial avoidanceABC-CFXAberrant Behavior Checklist-Community EditionHigh dose groupAnimal models of fragile X syndromeX syndromeModel of fragile X syndromeVineland Adaptive Behavior ScalesEffect sizeFlexible dose trialSerotonin reuptake inhibitorsSocial Avoidance subscaleChild studiesAdaptive Behavior ScalesAdolescent/adult studyFixed dose trialsDose groupParenting Stress IndexPhase 3 placebo-controlled trialsPreclinical models to clinical trialsResults of phase 3 trialsDose trial
2016
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial
Veenstra-VanderWeele J, Cook E, King B, Zarevics P, Cherubini M, Walton-Bowen K, Bear M, Wang P, Carpenter R. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology 2016, 42: 1390-1398. PMID: 27748740, PMCID: PMC5436109, DOI: 10.1038/npp.2016.237.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAutism spectrum disorderFragile X syndromeSpectrum disorderClinician-rated Clinical Global ImpressionAnimal models of fragile X syndromeGABA-BModel of fragile X syndromeSocial avoidance symptomsClinical Global ImpressionPlacebo-ControlledGABA-B agonistSubgroups of individualsPilot open-label trialExploratory post hoc analysisAffective labilityAvoidance symptomsPost hoc analysis of participantsOpen-label trialBehavioral phenotypesGlobal ImpressionArbaclofenSecondary analysisX syndromeSocial behaviorSocial domains
2014
Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder
Anagnostou E, Jones N, Huerta M, Halladay A, Wang P, Scahill L, Horrigan J, Kasari C, Lord C, Choi D, Sullivan K, Dawson G. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism 2014, 19: 622-636. PMID: 25096930, DOI: 10.1177/1362361314542955.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAutism spectrum disorderSpectrum disorderSymptom domainsEarly indicator of autism spectrum disorderMeasures of social communicationSocial communicationIndicator of autism spectrum disorderSocial communication impairmentsSocial communication measuresSocial communication deficitsSocial communication behaviorsCore deficitCommunication deficitsCommunication impairmentsAutism SpeaksPsychometric propertiesOutcome measuresAutismCommunication measuresTreatment targetCommunication behaviorsTreatment approachesDisordersMonthly conference callsTreatment endpoint
2013
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Erickson C, Veenstra-Vanderweele J, Melmed R, McCracken J, Ginsberg L, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter R, Bear M, Wang P, King B. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study. Journal Of Autism And Developmental Disorders 2013, 44: 958-964. PMID: 24272415, DOI: 10.1007/s10803-013-1963-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAutism spectrum disorderSpectrum disorderClinical Global Impression ScaleNon-syndromic autism spectrum disorderExcitatory to inhibitory neurotransmissionGlobal Impression ScaleSocial Responsiveness ScaleGABA-B agonistFragile X syndromeABC-irritabilityImpression ScaleWithdrawal subscalePlacebo-controlled studyAutistic disorderResponse scaleSTX209GABA-BX syndromeOpen-label studyInhibitory neurotransmissionArbaclofenDisordersSubscalesEvidence of benefitOpen-label